Eli lilly logo

Adding Baricitinib to COVID-19 Treatment Reduces Mortality by 44 Percent

August 6, 2021

Mechanically ventilated patients with COVID-19 were 44 percent less likely to die when Olumiant (baricitinib) was added to the standard treatment regimen, according to a substudy of Eli Lilly’s COV-BARRIER trial.

Among the 101 adult patients in the late-stage study, 45 percent of those taking baricitinib died compared to 62 percent of those taking placebo — a 44 percent reduction.

Mortality by day 28 was 46 percent lower, at 29.2 percent in the baricitinib arm and 58 percent in the placebo arm, the company reported.

View today's stories